Skip to main content

Fiscal Wizard · Single-issue tearsheet

AQST / Jun 21, 2026 Run #7395

AQST

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Composite verdict

F 0.0 / 100
Bearish setup · Oscillator 12 drivers · 6 gates blocking
  • Stochastic RSI
  • Williams %R
  • Commodity Channel Index
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 81st of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 33Mean-reversion Bearish 19

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

0.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Free Cash Flow Yield 0
FCF Margin 0
EBITDA Margin 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Stochastic RSI, Williams %R, Commodity Channel Index); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Stochastic RSI 9
Williams %R 10
Commodity Channel Index 12

Risk Gates

6 blocking 6 caution

6 guards active, 23 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for AQST.